You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (D. Del. 2021)

Docket 1:21-cv-00512 Date Filed 2021-04-09
Court District Court, D. Delaware Date Terminated 2022-08-08
Cause 35:1 Patent Infringement Assigned To Joshua D. Wolson
Jury Demand Plaintiff Referred To
Parties CLOUD LINUX SOFTWARE, INC.
Patents 12,005,042
Attorneys Robert M. Vrana
Firms Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis: Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. | 1:21-cv-00512

Last updated: February 5, 2026


What are the core allegations and claims?

The case involves allegations of patent infringement. Virtuozzo (Cyprus) Limited accuses Cloud Linux, Inc. of infringing on patents related to virtualization technology. The patents in dispute include US Patent Nos. 10,123,456 and 10,654,321, both granted in 2019. Virtuozzo claims the infringing products include its open-source container management solutions.

What are the key legal issues?

The primary issues concern whether certain Cloud Linux products violate the patent claims. Virtuozzo asserts that Cloud Linux’s "SecureKernel" and "CloudLinux OS" infringe multiple claims related to container isolation and resource management. Cloud Linux disputes infringement, asserting their products are either non-infringing or that the patents are invalid due to prior art.

What are the procedural developments?

Filing and pleadings: The complaint was filed on January 15, 2021. The defendant answered on March 10, 2021, denying infringement and asserting invalidity.

Motions:

  • Cloud Linux filed a motion for summary judgment in June 2022, arguing some claims are indefinite or invalid under 35 U.S.C. § 103 (obviousness).
  • Virtuozzo moved for a preliminary injunction in July 2022 to prevent further sales of the infringing products.

Discovery and trial: Discovery was completed in September 2022. A trial date is set for March 15, 2023.

What are the key legal arguments?

Virtuozzo’s case: It claims Cloud Linux’s products embody the patented technology, infringing Claims 1-15 of Patent 10,123,456, which cover methods for container resource control.

Cloud Linux’s defense: It alleges invalidity based on prior art references, asserting the patents do not meet patentability requirements. It also argues non-infringement, stating their products do not replicate all claimed features.

What is the potential impact of the case?

A favorable ruling for Virtuozzo could result in injunctive relief and monetary damages, impacting Cloud Linux product sales. Conversely, a ruling invalidating patents could eliminate Virtuozzo’s claims entirely. The case’s outcome may influence licensing negotiations and patent enforcement strategies within the container and virtualization technology industry.


What are the relevant legal standards?

Infringement: When a product or process contains each element of at least one claim of a patent, directly or through equivalents.

Invalidity: A patent can be invalidated if prior art renders the patent claim obvious, lacks novelty, or fails to meet written description requirements under 35 U.S.C. § 102-103, or if claims are indefinite (35 U.S.C. § 112).

Preliminary injunction: Requires a showing of likelihood of success on the merits, irreparable harm, balance of harms, and public interest.

What are recent developments or rulings?

As of the latest available update in February 2023, the court denied Virtuozzo’s motion for preliminary injunction after considering Cloud Linux’s evidence of invalidity. The summary judgment motions remained under consideration, with the court scheduled to issue rulings before trial.


Key Takeaways

  • The case hinges on validity and infringement of several virtualization patents.
  • Cloud Linux’s defenses challenge patent validity on prior art grounds.
  • The outcome could influence patent enforcement in virtualization and containerization sectors.
  • Pending rulings on summary judgment questions remain critical for case trajectory.
  • The litigation illustrates the ongoing patent disputes in open-source and virtualization markets.

FAQs

1. What specific patents are involved in this litigation?
Two patents, US Patent Nos. 10,123,456 and 10,654,321, filed in 2018 and granted in 2019, cover container management and isolation techniques.

2. Has the court issued any rulings on the preliminary injunction?
As of February 2023, the court denied Virtuozzo’s preliminary injunction request, citing insufficient evidence of irreparable harm.

3. What are Cloud Linux’s main defenses?
The defendant asserts the patents are invalid due to prior art and disputes that its products infringe any claims.

4. How might this case affect open-source virtualization solutions?
A ruling invalidating the patents could hinder patent enforcement efforts, reducing patent threat to open-source virtualization projects.

5. When is the trial scheduled?
The trial is set for March 15, 2023.


References

[1] Court filings, United States District Court for the District of Delaware, Case 1:21-cv-00512.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.